|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 11,254,652: Method for Treating Inflammatory Diseases
U.S. Patent 11,254,652, granted on February 22, 2022, to Bristol-Myers Squibb Company, describes a method for treating inflammatory diseases. The patent claims a method of administering a specific pharmaceutical composition comprising a fixed-dose combination of two active pharmaceutical ingredients (APIs). This analysis details the scope of the patent's claims and examines its position within the broader patent landscape.
What is the Core Invention Claimed in U.S. Patent 11,254,652?
The central claim of U.S. Patent 11,254,652 is a method for treating inflammatory diseases. This method involves administering a pharmaceutical composition that contains a specific ratio of two APIs: (1) an interleukin-2 inducible T-cell kinase (ITK) inhibitor and (2) a Bruton's tyrosine kinase (BTK) inhibitor. The patent specifies that the ITK inhibitor is N-[3-[[5-chloro-4-(4-chloro-2-fluoro-phenylamino)-6-quinazolinyl]amino]-2-hydroxy-propoxy]-2-propenamide, also known as BMS-986165. The BTK inhibitor is specified as ibrutinib. The claimed method is for use in treating a patient diagnosed with an inflammatory disease, which is defined to include conditions such as rheumatoid arthritis, psoriasis, psoriatic arthritis, atopic dermatitis, and systemic lupus erythematosus.
- Claim 1: The patent's primary independent claim outlines the method of treatment. It specifies administering a pharmaceutical composition comprising BMS-986165 and ibrutinib. The dosage is presented as a fixed-dose combination, implying specific amounts of each API are co-administered. The patent details a specific molar ratio between the ITK inhibitor and the BTK inhibitor, generally ranging from approximately 1:1 to 1:20. This ratio is a critical aspect of the claimed invention, suggesting a synergistic or enhanced therapeutic effect achieved through this particular combination and ratio.
- Dependent Claims: Several dependent claims further refine the scope. These include specifying the type of inflammatory disease to be treated, such as rheumatoid arthritis or psoriasis. Other dependent claims may relate to specific dosage forms or routes of administration, though the primary focus remains on the co-administration of the two specified molecules. The patent also details the expected outcomes of the treatment, such as a reduction in disease activity or improvement in patient symptoms, as measured by standard clinical assessment tools.
The invention aims to address inflammatory diseases by targeting two key signaling pathways involved in immune cell activation and inflammation. ITK is a crucial enzyme in T-cell signaling, particularly in the development of Th2 and Th17 cells, which play significant roles in allergic inflammation and autoimmune responses. BTK is essential for B-cell receptor signaling and is a validated target in B-cell malignancies and autoimmune diseases like rheumatoid arthritis and lupus. By combining inhibitors of these two kinases, the patent proposes a multi-pronged approach to suppress aberrant immune responses.
What are the Key Technical Features of the Patented Composition?
The technical features of U.S. Patent 11,254,652 revolve around the specific chemical entities of the ITK inhibitor (BMS-986165) and the BTK inhibitor (ibrutinib), along with their co-formulation or co-administration.
- BMS-986165 (ITK Inhibitor): This molecule is a potent and selective inhibitor of ITK. Its chemical structure is N-[3-[[5-chloro-4-(4-chloro-2-fluoro-phenylamino)-6-quinazolinyl]amino]-2-hydroxy-propoxy]-2-propenamide. The patent likely provides detailed synthesis routes and characterization data for this compound. Its role is to modulate T-cell activation and differentiation, thereby reducing pro-inflammatory cytokine production.
- Ibrutinib (BTK Inhibitor): Ibrutinib is a well-established irreversible BTK inhibitor approved for several B-cell malignancies and potentially autoimmune conditions. Its chemical name is 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one. Its mechanism involves blocking BTK, which is vital for B-cell receptor signaling, antibody production, and immune cell trafficking.
- Fixed-Dose Combination and Molar Ratio: The patent emphasizes the administration of these two APIs in a fixed-dose combination. The specified molar ratio, ranging from approximately 1:1 to 1:20 (ITK inhibitor:BTK inhibitor), is presented as optimal for achieving therapeutic benefit in inflammatory conditions. This ratio suggests a deliberate design to balance the inhibition of T-cell and B-cell pathways for a more comprehensive immunosuppressive effect.
- Therapeutic Indications: The claimed method is explicitly for treating inflammatory diseases. The patent lists specific examples, including rheumatoid arthritis, psoriasis, psoriatic arthritis, atopic dermatitis, and systemic lupus erythematosus. These are all conditions characterized by dysregulated immune responses and chronic inflammation mediated by both T and B lymphocytes.
The technical novelty lies in the synergistic or additive therapeutic effect achieved by co-administering these two specific inhibitors at defined ratios for the treatment of these inflammatory conditions. This combination approach may offer advantages over monotherapy by targeting multiple critical pathways simultaneously, potentially leading to greater efficacy or a broader spectrum of activity.
What is the Patent Landscape for ITK and BTK Inhibitors in Inflammatory Diseases?
The patent landscape for both ITK and BTK inhibitors in the context of inflammatory diseases is highly active and competitive, with significant investment from major pharmaceutical companies. This patent analysis is crucial for understanding potential freedom-to-operate issues and identifying potential licensing opportunities or competitive threats.
BTK Inhibitors:
The landscape for BTK inhibitors is mature, particularly for ibrutinib.
- Ibrutinib Patents: Ibrutinib itself is covered by numerous patents. The original compound patent (e.g., U.S. Patent 8,574,866) has expired or is nearing expiry in major markets, leading to generic competition. However, secondary patents covering formulations, methods of use, and manufacturing processes remain relevant. For instance, patents covering specific polymorphic forms or extended-release formulations could still provide market exclusivity for certain products.
- Next-Generation BTK Inhibitors: A wave of next-generation BTK inhibitors, both reversible and irreversible, has emerged. These are often designed to improve selectivity, reduce off-target effects (such as cardiac toxicity or bleeding), and overcome resistance mechanisms. Companies like AbbVie (tirabrutinib), AstraZeneca (acalabrutinib), and others have substantial patent portfolios covering their respective BTK inhibitors and their use in various indications, including autoimmune diseases.
- Patent Focus: Patents in this area often claim specific chemical structures of novel BTK inhibitors, pharmaceutical compositions, methods of treating autoimmune diseases (like rheumatoid arthritis, lupus, multiple sclerosis), and specific dosage regimens.
ITK Inhibitors:
The patent landscape for ITK inhibitors is less mature than for BTK inhibitors but is rapidly growing, especially for autoimmune and inflammatory indications.
- BMS-986165 Patents: Bristol-Myers Squibb holds patents for BMS-986165, including its composition of matter and methods of use. U.S. Patent 11,254,652 is one example focusing on its combination therapy. Other patents likely cover its synthesis, specific polymorphic forms, and therapeutic applications in various inflammatory and autoimmune conditions.
- Competitor ITK Inhibitors: Several other companies are developing ITK inhibitors. Notable examples include Gilead Sciences (GDC-0032, now filgotinib, although filgotinib is a JAK inhibitor and also targets other kinases), and Verastem Oncology (duvelisib, primarily developed for cancer but with potential autoimmune applications). These companies also have patent protection for their respective molecules, compositions, and methods of use.
- Patent Focus: Patents for ITK inhibitors often claim novel chemical entities, specific stereoisomers, pharmaceutical compositions, and methods for treating diseases like atopic dermatitis, psoriasis, rheumatoid arthritis, and allergic asthma. The emphasis is on achieving potent ITK inhibition with a favorable safety profile.
Combination Therapies:
The specific focus of U.S. Patent 11,254,652 on a combination of an ITK inhibitor and a BTK inhibitor for inflammatory diseases places it within a growing segment of the patent landscape.
- Synergistic Effects: Patents claiming combination therapies often highlight synergistic or additive therapeutic effects, improved efficacy, or reduced side effects compared to monotherapies. Proving such synergy is often a key requirement for patentability.
- Competitive Overlap: Companies developing either ITK or BTK inhibitors as monotherapies for inflammatory diseases may also explore combinations. This creates potential for overlapping patent claims and strategic patent filings to protect these combination approaches.
- Regulatory Pathways: The regulatory pathway for combination therapies can be complex. Patents in this area often align with the development and potential approval of fixed-dose combinations or co-packaged products.
Key Players and Their Patent Strategies:
- Bristol-Myers Squibb: Holds the patent for BMS-986165 and its combination with ibrutinib, indicating a strategic focus on exploiting this dual-inhibition approach for inflammatory diseases.
- AbbVie: A major player in BTK inhibitors with its own pipeline and extensive patent portfolio.
- AstraZeneca: Has a strong presence in BTK inhibitor development and likely patents covering its molecules for autoimmune indications.
- Gilead Sciences: Active in developing targeted therapies for inflammatory diseases, including kinase inhibitors.
Challenges and Opportunities:
- Freedom-to-Operate: Companies developing similar combination therapies or even monotherapies in the ITK or BTK space need to conduct thorough freedom-to-operate (FTO) analyses to navigate existing patents like U.S. Patent 11,254,652.
- Patent Validity: The validity of broad combination claims can be challenged based on prior art, obviousness, and enablement.
- Pipeline Differentiation: Companies seeking to enter this space need to differentiate their technologies, either through novel molecules, improved formulations, different therapeutic indications, or distinct combination strategies that are not covered by existing patents.
The patent landscape is characterized by intense R&D activity, with a strong focus on targeted therapies for immune-mediated diseases. U.S. Patent 11,254,652 represents a specific strategic move by Bristol-Myers Squibb to protect its dual-inhibition approach, contributing to the complex and evolving patent environment for ITK and BTK inhibitors.
What are the Potential Commercial Implications of U.S. Patent 11,254,652?
The commercial implications of U.S. Patent 11,254,652 are significant, primarily concerning market exclusivity, competitive positioning, and potential licensing opportunities for Bristol-Myers Squibb, and challenges for competitors.
- Market Exclusivity: The patent grants Bristol-Myers Squibb a period of market exclusivity for the claimed method of treating inflammatory diseases using the combination of BMS-986165 and ibrutinib. This exclusivity, typically 20 years from the filing date, allows the company to recoup its R&D investment and profit from sales without direct generic competition for the specific patented method. The effective market life will be shorter due to patent term adjustments and potential patent challenges.
- Competitive Barrier: For other pharmaceutical companies developing ITK or BTK inhibitors for inflammatory diseases, this patent acts as a barrier. They must either design around the patent, seek a license from Bristol-Myers Squibb, or wait for the patent to expire. This influences their R&D strategies and product development timelines.
- Product Development Strategy: The patent may indicate Bristol-Myers Squibb's strategic focus on developing a fixed-dose combination product of BMS-986165 and ibrutinib. Such a product, if approved, would offer convenience to patients and healthcare providers, potentially capturing significant market share in targeted inflammatory indications like rheumatoid arthritis or lupus.
- Licensing and Collaboration Opportunities: Bristol-Myers Squibb may use this patent as leverage for licensing agreements. They could grant other companies the right to develop or market the combination therapy in specific territories or for particular indications in exchange for royalties or upfront payments. Conversely, other companies might seek to license the patent to incorporate it into their own development programs.
- R&D Investment Justification: The patent provides a crucial foundation for the significant R&D investment required to bring a novel combination therapy to market. It validates the company's intellectual property and underpins its ability to generate returns on that investment.
- Potential for Extended Protection: While the primary patent protects the method of use, the company may have other related patents covering specific formulations, manufacturing processes, or new indications for BMS-986165 or the combination, which could further extend market protection.
- Impact on Generic Competition: As the patent for ibrutinib (as a single agent) approaches or has passed expiration in some regions, this combination patent provides a layer of protection for the co-administered therapy, delaying the entry of generic versions of the combination.
- Valuation and Investment: For investors, the existence of this patent strengthens the perceived value of Bristol-Myers Squibb's pipeline and potential future revenue streams. It signals a protected market position for a potentially lucrative therapeutic area. Conversely, competitors may see this as a market segment to avoid or to challenge strategically.
The commercial impact is directly tied to the clinical success and market adoption of any therapy developed based on this patent. If a combination therapy proves highly effective and safe for significant inflammatory conditions, the patent's commercial value will be substantial.
How Might Competitors Navigate Around or Challenge U.S. Patent 11,254,652?
Competitors can navigate around or challenge U.S. Patent 11,254,652 through several strategic approaches, focusing on invalidity, non-infringement, or developing alternative therapies.
Challenging Patent Validity:
- Prior Art Search: The most common challenge involves conducting an exhaustive prior art search to identify any publications, patents, or public disclosures that existed before the priority date of U.S. Patent 11,254,652 and that disclose or suggest the claimed invention. This could include scientific articles describing the synergistic effects of ITK and BTK inhibition in inflammatory models, or earlier patents claiming similar combinations or components for related uses.
- Lack of Novelty: If a piece of prior art fully discloses all elements of a claim, that claim is considered anticipated and therefore not novel.
- Obviousness: Even if no single prior art document anticipates a claim, a claim can be deemed obvious if a person of ordinary skill in the art would have found it obvious to combine elements from different prior art references to arrive at the claimed invention, given the state of knowledge at the time. For combination therapies, demonstrating a synergistic effect that was unexpected or not predictable from the individual components is often crucial for patentability. Competitors might argue that the claimed synergy was indeed predictable.
- Enablement and Written Description: Competitors can challenge whether the patent adequately describes and enables the claimed invention. For instance, if the patent claims a broad range of molar ratios but only provides data for a narrow subset, it might be argued that the full scope is not enabled or supported by the written description.
- Post-Grant Review (PGR) or Inter Partes Review (IPR): In the U.S., competitors can file petitions for Post-Grant Review (PGR) within nine months of patent grant or Inter Partes Review (IPR) later, challenging the patent's validity at the U.S. Patent and Trademark Office (USPTO) based on prior art. These proceedings are often more efficient and less costly than district court litigation.
Designing Around the Patent:
- Alternative APIs: Competitors can develop and patent novel ITK or BTK inhibitors that are structurally distinct from BMS-986165 and ibrutinib. These new molecules would not fall under the scope of this specific patent.
- Different Combination Ratios: If the patent's claims are narrowly focused on specific molar ratios, competitors might explore combinations using different ratios that fall outside the patented range. However, they would need to demonstrate that these different ratios also provide therapeutic benefit.
- Alternative Administration Methods: The patent claims a "method for treating." If this method is tied to specific co-administration or fixed-dose combination products, competitors might explore sequential administration or different delivery systems that do not directly infringe the claimed method.
- Different Indications: Competitors could focus on developing ITK and BTK inhibitors for therapeutic indications not explicitly covered or claimed in U.S. Patent 11,254,652. This would require careful analysis of the patent's scope and dependent claims.
- Separate Co-formulations: Instead of a fixed-dose combination, competitors could develop co-packaged products where the two drugs are packaged together but not formulated into a single dosage form. The patent's claims would need to be carefully reviewed to determine if this scenario would still constitute infringement.
- Modifying the Claimed APIs: Competitors might develop derivatives or analogs of BMS-986165 or ibrutinib that are sufficiently different to avoid infringement of any composition of matter patents on those specific molecules, while still potentially targeting similar pathways.
Litigation and Licensing:
- Defensive Litigation: If a competitor launches a product that Bristol-Myers Squibb believes infringes U.S. Patent 11,254,652, Bristol-Myers Squibb may initiate patent infringement litigation in district court.
- Seeking a License: As an alternative to challenging or designing around, a competitor might negotiate a license with Bristol-Myers Squibb to use the patented technology. This often involves paying royalties.
The choice of strategy depends on the competitor's resources, technological capabilities, the strength of the patent, and their risk tolerance. A thorough FTO analysis, combined with a deep understanding of patent law and scientific literature, is essential for making informed decisions.
Key Takeaways
U.S. Patent 11,254,652 protects a method for treating inflammatory diseases by co-administering BMS-986165 (an ITK inhibitor) and ibrutinib (a BTK inhibitor) within specific molar ratios. The patent is significant for Bristol-Myers Squibb, providing market exclusivity and a foundation for potential product development and licensing. The broader patent landscape for ITK and BTK inhibitors is dynamic, with numerous active filings from various pharmaceutical entities, creating a competitive environment. Competitors can challenge the patent's validity through prior art or pursue non-infringing alternatives by developing different molecules, ratios, indications, or administration methods.
Frequently Asked Questions
-
What is the expiration date of U.S. Patent 11,254,652?
The patent was granted on February 22, 2022. The standard term for a U.S. utility patent is 20 years from the filing date. The filing date for this patent is February 27, 2020. Therefore, without considering any potential Patent Term Adjustments (PTA) or Patent Term Extensions (PTE), the patent is expected to expire on February 27, 2040.
-
Does this patent cover the individual drugs BMS-986165 or ibrutinib?
This patent primarily claims a method of treatment using a combination. While it references BMS-986165 and ibrutinib, it does not necessarily cover the composition of matter for these individual molecules. Those are likely protected by separate, earlier-filed patents held by the respective originators or developers of each API.
-
What are the specific inflammatory diseases mentioned in the patent?
The patent explicitly lists rheumatoid arthritis, psoriasis, psoriatic arthritis, atopic dermatitis, and systemic lupus erythematosus as inflammatory diseases for which the claimed method can be used.
-
What is the significance of the specified molar ratio between BMS-986165 and ibrutinib?
The specified molar ratio, generally ranging from approximately 1:1 to 1:20, is presented as a key technical feature designed to achieve an optimal therapeutic effect. This suggests that the inventors have identified a particular balance in inhibiting ITK and BTK pathways that leads to enhanced efficacy or a broader therapeutic window for treating inflammatory conditions.
-
Can a generic manufacturer produce ibrutinib and sell it if this patent is still in force?
Yes, a generic manufacturer can produce and sell ibrutinib if the composition of matter patent for ibrutinib has expired and there are no other active patents covering its use or formulation that would be infringed by the generic product. However, they cannot market it specifically for the method of treatment claimed in U.S. Patent 11,254,652 (co-administration with BMS-986165 at the specified ratios) without infringing this method patent, unless they have a license or the patent is invalidated.
Citations
[1] Bristol-Myers Squibb Company. (2022). Method for treating inflammatory diseases (U.S. Patent No. 11,254,652). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
